Nuwellis to Present at the Gilmartin Group Emerging Growth Showcase
- S&P 500 and Nasdaq notch highest closes since early 2022
- U.S. economy adds 199,000 jobs in November
- Fed should 'lowball' rate cuts expectations next week says analyst after strong jobs data
- Bernstein's best idea for 2024? Short Tesla stock
- Analysts defend Broadcom as annual guidance falls short after FQ4 earnings beat
MINNEAPOLIS, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company dedicated to transforming the lives of people with fluid overload, today announced that President and Chief Executive Officer Nestor Jaramillo, Chief Financial Officer Rob Scott, and Chief Medical Officer Dr. John Jefferies, will participate in a fireside chat at the upcoming Gilmartin Group Emerging Growth Showcase on Thursday, September 21, 2023, at 12:00 pm ET.
To access the live webcast, please visit the Investors page of the Nuwellis website. To ask a question, please feel free to send your questions ahead of time to [email protected]. The webcast will be available for replay on Nuwellis’ investor relations website at https://ir.nuwellis.com/.
Nuwellis, Inc. (Nasdaq: NUWE) is a medical technology company dedicated to transforming the lives of patients suffering from fluid overload through science, collaboration, and innovation. The company is focused on commercializing the Aquadex SmartFlow® system for ultrafiltration therapy. Nuwellis is headquartered in Minneapolis, Minnesota with a wholly owned subsidiary in Ireland. For more information visit www.nuwellis.com or visit us on LinkedIn.
About the Aquadex SmartFlow® System
The Aquadex SmartFlow system delivers clinically proven therapy using a simple, flexible, and smart method of removing excess fluid from patients suffering from hypervolemia (fluid overload). The Aquadex SmartFlow system is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a health care provider, within an outpatient or inpatient clinical setting, under physician prescription, both having received training in extracorporeal therapies.
INVESTORS:Vivian CervantesGilmartin Group LLC[email protected]
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Par Pacific Announces Hawaii Renewable Cogeneration Facility Development Plans
- China Petroleum & Chemical Corporation Intends to Deregister and Terminate Its Reporting Obligations Under the U.S. Securities Exchange Act of 1934
- KBW Announces Index Rebalancing for Fourth-Quarter 2023
Create E-mail Alert Related CategoriesGlobe Newswire, Press Releases
Related EntitiesJefferies & Co
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!